fig2

Figure 2. Conceptual treatment continuum of osimertinib across disease stages (Sankey diagram). Note: This diagram represents a synthesized, evidence-informed conceptual framework illustrating the treatment flow across clinical scenarios rather than a strictly data-derived patient-level analysis. Treatment transitions are based on current guideline recommendations and pivotal trial evidence (ADAURA, LAURA, FLAURA, FLAURA2, AURA3). The bifurcation between osimertinib monotherapy and osimertinib plus chemotherapy in the first-line advanced setting reflects the risk-stratified approach informed by FLAURA2 data, where high-risk features (e.g., TP53 comutation, high tumor burden, and L858R mutation) may favor combination therapy. Dashed lines indicate emerging or investigational pathways not yet established as the standard of care.